Incorporating Precision Medicine into Oncology

Video

In Partnership With:

Terrill Jordan, LLM, JD, MAcc, discusses challenges regarding the utility of precision medicine in oncology.

Terrill Jordan, LLM, JD, president and chief executive officer, Regional Cancer Care Associates, discusses challenges regarding the utility of precision medicine in oncology.

There is a robust pipeline of drugs in development in oncology, explains Jordan. The number of agents that are poised to enter the market may complicate current treatment strategies.

Notably, precision medicine has helped individualize treatment for patients. Among the flood of new agents, physicians should consider patient-specific factors when choosing a treatment.

Precision medicine can be costly; however, it appears to be cost-effective in the long-term, concludes Jordan.

Related Videos
Vishal Patel, MD, FAAD, FACMS, associate professor, Dermatology, George Washington (GW) School of Medicine & Health Sciences
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP